12月19日，首届进博优品交易会在国家会展中心（上海）开幕。全球领先的生物制药公司赛诺菲携多 款"从展台走向市场"的进博明星展品亮相本次展会。作为连续八年的"全勤"参展商，赛诺菲已确认参展 第九届中国国际进口博览会（以下简称"进博会"），将持续依托这一国家级开放窗口，链接全球创新资 源与多元健康需求，支持中国医疗健康事业高质量发展。 赛诺菲大中华区总裁施旺表示："八年来，进博会见证了赛诺菲的许多关键创新从'第一次在中国亮 相'，到真正走进临床、走到患者身边。这些被大家亲切称为'进博宝宝'的产品，之所以备受关注，是因 为它们代表了赛诺菲全球最前沿的研发成果，也承载了患者对先进治疗的迫切期待。进博会以其独特的 平台价值，让创新能够更快地从科学愿景变为健康解决方案。明年，我们将继续参与进博会，把更具突 破性的全球创新带到中国，为中国医疗体系和每一位患者创造更实在的价值。" 赛诺菲亮相首届进博优品交易会 从进博首秀到临床实践，创新成果加速惠及患者 作为进博会的长期伙伴，赛诺菲始终以进博会为纽带，加速引进全球创新疗法、持续深化本土布局、链 接创新生态，以实际行动履行与中国同心同行的坚定承诺。在第八届进博会上，赛诺菲以" ...

Core Insights - The China International Import Expo (CIIE) serves as a significant platform for high-level opening-up, showcasing cutting-edge medical innovations from top global healthcare companies, with a focus on the integration of medical insurance and pharmaceutical industries [1][4][8] Group 1: Innovation in Pharmaceuticals and Medical Devices - The CIIE has accelerated the entry of innovative drugs and medical devices into the Chinese market, with 43 innovative drugs and 45 innovative medical devices approved in the first half of the year, representing year-on-year increases of 59% and 87% respectively [2] - Sanofi's product "Dupixent" exemplifies the CIIE's impact, having transitioned from debut to market approval and inclusion in the national medical insurance directory [2] - Merck showcased around 30 approved drugs and vaccines at the CIIE, including several innovative drugs making their debut in China [2][3] Group 2: Medical Insurance Integration - The integration of commercial health insurance (商保) into the medical payment system is evolving, with the National Medical Insurance Administration introducing a commercial insurance innovative drug directory [4] - The shift towards a multi-channel payment system is crucial for meeting the growing medical needs as innovative drugs proliferate [4][7] - The health insurance market is entering a new development phase, with a focus on group health insurance as a potential growth area, currently accounting for 15% to 20% of the market compared to over 50% in overseas markets [7] Group 3: Future Prospects and Challenges - Despite progress in multi-channel payment mechanisms, challenges remain, with the innovative drug market projected to reach 162 billion yuan in 2024, and commercial insurance expected to cover only 12.4 billion yuan, or 7.7% of the market [7] - The CIIE has witnessed the participation of China Pacific Insurance for the first time, highlighting the trend of integrating medical insurance with pharmaceutical innovations [7] - The development of group health insurance is seen as a key opportunity, with initiatives underway to enhance coverage for employees' out-of-pocket medical expenses [7][8]

Core Viewpoint - Sanofi is actively contributing to the "Healthy China" initiative by showcasing innovative drugs and vaccines at the 8th China International Import Expo, focusing on major health issues such as cardiovascular diseases, metabolic disorders, respiratory diseases, and cancer [1][2]. Group 1: Innovative Products and Collaborations - Sanofi presented ten first-in-class or best-in-class innovative products, including two groundbreaking cardiovascular therapies making their global debut: Afikaytai tablets and Pulesiran sodium injection [2][3]. - The company is deepening strategic collaborations with local partners to enhance the pharmaceutical innovation ecosystem in China, exemplified by the establishment of the Sanofi-Kaihui Pharmaceutical Innovation Fund [2][3]. Group 2: Commitment to Local Development - Sanofi has been accelerating the approval and market entry of innovative drugs in China, evidenced by the successful launch of multiple products, including the first targeted therapy for immune-mediated thrombotic thrombocytopenic purpura [4][5]. - The company is transitioning from being an exhibitor to an investor, increasing its investment in local production and innovation, including a recent €1 billion investment in a Beijing insulin raw material project [6].

Group 1 - The eighth China International Import Expo (CIIE) is set to take place from November 5 to 10 in Shanghai, with the theme "New Era, Shared Future" [1] - The expo will feature six major exhibition areas, including an upgraded "Automobile and Smart Mobility Exhibition Area" and a focus on global top medical technology achievements in the medical exhibition area [2] - A special area for least developed countries' products will be established for the first time, promoting the use of "zero tariff" policies for enterprises from these nations [2] Group 2 - New initiatives for enhancing supply-demand matching efficiency include tailored strategies for groups, an online registration system for group visits, and a comprehensive online supply-demand platform [3] - The exhibition will optimize digital services and reduce some service fees to enhance the overall experience for exhibitors [3] Group 3 - Over 50 countries and international organizations have confirmed participation, with Sweden and the UAE serving as guest countries, and Kyrgyzstan making its debut at the expo [4] - A record number of enterprises from Canada, Malaysia, and New Zealand will participate, with new provincial and municipal representations from Saskatchewan and Almaty [4] Group 4 - Boston Scientific will showcase several innovative products, including the Intera 3000 liver perfusion pump and the FARAPULSE ablation system, emphasizing the importance of the expo for deepening cooperation in China [5] - Sanofi will highlight its innovative drugs, including Dupixent and the first RSV prevention drug for infants, showcasing the expo as a platform for accelerating innovation [5] Group 5 - The expo aims to strengthen the three key characteristics of "innovation-driven, consumption upgrade, and inclusive development," contributing to global economic recovery through international procurement and investment promotion [6]